NSCLC患者血清中PTBP1、CDCP1的表达及临床预后意义  

Expression and clinical prognostic significance of PTBP1 and CDCP1 in serum of NSCLC patients

作　　者：熊云刚[1] 成克伦[1] 赵露 姜森[1] 顾延会 XIONG Yungang;CHENG Kelun;ZHAO Lu;JIANG Sen;GU Yanhui(Department of Pathology,Guizhou Aerospace Hospital,Zunyi,Guizhou 563000,China;Frist Department of Respiration,Affiliated Hospital of Zunyi Medical University,Zunyi,Guizhou 563000,China)

机构地区：[1]贵州航天医院病理科,贵州遵义563000 [2]遵义医科大学附属医院呼吸一科,贵州遵义563000

出　　处：《国际检验医学杂志》2023年第12期1507-1511,1521,共6页International Journal of Laboratory Medicine

基　　金：遵义市科技合作项目(遵市科合HZ字[2021]178号);贵州省科技计划项目(黔科合成果[2019]4434号)。

摘　　要：目的 探讨非小细胞肺癌(NSCLC)患者血清中多聚嘧啶束结合蛋白1(PTBP1)、含CUB结构域的蛋白质1(CDCP1)的表达及临床预后意义。方法 选取于贵州航天医院就诊的90例NSCLC患者为NSCLC组,以同期诊治的40例肺部良性疾病患者为良性疾病组,40例体检健康者为对照组。采用酶联免疫吸附试验检测各组血清PTBP1、CDCP1水平,并比较各组血清PTBP1、CDCP1水平差异,比较不同临床病理特征患者血清PTBP1、CDCP1水平差异。采用Pearson相关分析NSCLC组血清PTBP1与CDCP1水平的相关性,采用Kaplan-Meier生存曲线分析血清PTBP1、CDCP1水平对NSCLC患者生存预后的影响,采用单因素及多因素Cox回归分析影响NSCLC患者生存预后的因素。结果 NSCLC组血清PTBP1、CDCP1水平明显高于良性疾病组和对照组,差异均有统计学意义(P<0.05)。NSCLC组患者血清PTBP1与CDCP1水平呈正相关(r=0.721,P<0.001)。不同肿瘤分期、淋巴结转移患者血清PTBP1、CDCP1水平差异有统计学意义(P<0.05)。PTBP1高表达组和低表达组NSCLC患者的平均生存时间分别为(27.59±3.32)个月、(31.47±3.68)个月,Kaplan-Meier生存曲线分析结果显示,PTBP1高表达组患者累积生存率低于PTBP1低表达组患者(χ^(2)=5.910,P=0.015)。CDCP1高表达组和低表达组平均生存时间分别为(27.34±3.29)个月、(32.27±3.54)个月,CDCP1高表达组患者累积生存率低于CDCP1低表达组患者(χ^(2)=7.544,P=0.006)。肿瘤分期Ⅲ~Ⅳ期、有淋巴结转移、PTBP1高表达、CDCP1高表达是影响NSCLC患者生存预后的独立危险因素。结论 NSCLC患者血清PTBP1、CDCP1水平升高,二者与肿瘤分期及淋巴结转移有关,是影响NSCLC患者生存预后的独立危险因素,二者是潜在的NSCLC肿瘤标志物。Objective To investigate the expression and prognostic significance of polypyrimidine bundle binding protein 1(PTBP1)and CUB domain-containing protein 1(CDCP1)in serum of non-small cell lung cancer(NSCLC)patients.Methods Totally 90 patients with NSCLC in Guizhou Aerospace Hospital were selected as the NSCLC group,40 patients with benign pulmonary disease were selected as the benign disease group,and 40 healthy people were selected as the control group.The levels of serum PTBP1 and CDCP1 in each group were detected by enzyme-linked immunosorbent assay,and the differences of serum PTBP1 and CDCP1 levels in each group were compared,and the differences of serum PTBP1 and CDCP1 levels in patients with different clinicopathological characteristics were compared.Pearson correlation analysis was used to analyze the correlation between serum PTBP1 and CDCP1 levels in NSCLC patients.Kaplan-Meier survival curve was used to analyze the effect of serum PTBP1 and CDCP1 levels on the survival and prognosis of NSCLC patients.Univariate and multivariate Cox regression analysis were used to analyze the factors affecting the survival and prognosis of NSCLC patients.Results The levels of serum PTBP1 and CDCP1 in NSCLC group were significantly higher than those in benign disease group and control group,and the differences were statistically significant(P<0.05).There was a positive correlation between serum PTBP1 and CDCP1 levels in NSCLC patients(r=0.721,P<0.001).There were significant differences in serum PTBP1 and CDCP1 levels among patients with different tumor stages and lymph node metastasis(P<0.05).The mean survival times of NSCLC patients with high and low PTBP1 expression group were(27.59±3.32)months and(31.47±3.68)months,respectively.Kaplan-Meier survival curve analysis showed that the cumulative survival rate of PTBP1 high expression group was lower than that of PTBP1 low expression group(χ^(2)=5.910,P=0.015).The mean survival times of CDCP1 high expression group and low expression group were(27.34±3.29)months and(32.27

关 键 词：非小细胞肺癌 多聚嘧啶束结合蛋白1 含CUB结构域的蛋白质1 预后 

分 类 号：R734.2[医药卫生—肿瘤]